Marshall Wace, LLP Leap Therapeutics, Inc. Transaction History

Marshall Wace, LLP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$0.42 - $0.78 $67,178 - $124,759	-159,948 Reduced 25.7%	462,430 $208,000
Q3 2022 Nov 14, 2022	SELL	$0.92 - $1.75 $173,932 - $330,849	-189,057 Reduced 23.3%	622,378 $547,000
Q2 2022 Aug 15, 2022	SELL	$0.96 - $1.91 $757,351 - $1.51 Million	-788,908 Reduced 49.3%	811,435 $933,000
Q1 2022 May 16, 2022	BUY	$1.6 - $3.35 $1.09 Million - $2.28 Million	680,102 Added 73.9%	1,600,343 $2.8 Million
Q4 2021 Feb 14, 2022	BUY	$2.08 - $3.65 $1.91 Million - $3.36 Million	920,241 New	920,241 $2.98 Million

265K

Ticker LPTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,021,400
Market Cap $198M
Description
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate can...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.